
We observe a 28% elevation above trend in cancer treatment expenditures (panel 1) and pose the critical-path question: could this simply reflect sector inflation and/or unit price escalation? The analysis is conducted in sector-constant-dollars, and we examined the top 50 cancer drugs for Medicare Part D dosage unit growth (panel 2). (You won't see the trolls doing this type of intelligence work...) The answer is no. This reflects a real increase in cancer incidence, earlier age of onset, and greater case aggressiveness — factors which compound to drive observed dosage unit demand. This dynamic is consistent with the excess mortality observed in panel 3, which, given these underlying drivers, is likely to accelerate further, unfortunately.








































